Successfully reported this slideshow.

BioProcess International Keynote

1,557 views

Published on

Published in: Business, Economy & Finance
  • Be the first to comment

BioProcess International Keynote

  1. 1. The Role of Biosimilars in Driving Innovation in the Biopharmaceutical Industry Thomas Vanden Boom, Ph.D. Vice President, Hospira Global Biologics R&D BioProcess International Convention Providence, Rhode Island September 23, 2010
  2. 2. Biosimilars Regulatory Framework Continues to Evolve Worldwide WHO 2009 WHO 2009 Canada 2010 Canada 2010 US 2010 US 2010 Europe 2005 Europe 2005 Japan 2009 Japan 2009 Australia 2006 Australia 2006 Dates represent year when primary guidelines, guidance or legislation adopted
  3. 3. Growing Biologics Market Driving Interest in Biosimilars Space Rest-of-World $18 B Rest-of-World $18 B Europe $26 B Europe $26 BUS $50 B US $50 B Japan $6 B Japan $6 B 2009 Global Biologic Sales2009 Global Biologic Sales Source: Hospira analysis of Datamonitor IMS data, December 2009
  4. 4. Biosimilars Represent a Distinct New Sector of the Biopharmaceutical Industry Biosimilars Originator Products Generics Development Environment Development Environment Probability of Success Cost Time Development Low (~30%)High (~90%) High (>$800 M)Low (<$5 M) Long (8-12 yrs)Short (3-4 yrs) Barriers to Entry Point of Differentiation Other Dynamics HighLow Product profile, marketing Price, breadth of portfolio Competitors Investment Pricing Marketing Few, well differentiated Many, little differentiation HighLow PremiumCommodity Source: FTC Report June 2009 and HSP internal analysis
  5. 5. What is the state of innovation in the industry?
  6. 6. 0 10 20 30 40 50 60 1996 2000 2005 2009 0 10 20 30 40 50 60 70 NDA BLA R&D Investment 6 FDA approvals used as a frequent measure of biopharmaceutical industry innovation (and productivity) R&DInvestment($USB) FDAApprovals Adopted from Nature Rev. Drug Discov. 9, 89-92; 2010 and http://www.phrma.org/key_industry_facts_about_phrma
  7. 7. 7 Executive Survey Rankings of Top 50 Most Innovative Companies Survey Number of Biopharmaceutical Companies in Top 50 Ranking Boston Consulting Group/ BusinessWeek 0 FastCompany 2 Source: Innovation 2010: A Return to Prominence-and the Emergence of a New World Order, A BCG Senior Management Survey, January 2010 and FastCompany Issue 143, March 2010
  8. 8. Innovation Executive Survey Results BCG Innovation Survey Results by Industry Number Company 1 Pfizer 2 GlaxoSmithKline 3 Bayer 4 Novartis Corporation 5 Merck & Company Number Company 8 Novartis Corporation 26 Synthetic Genomics FastCompany Top 50 Innovation Survey Results
  9. 9. What impact do biopharma insiders think biosimilars will have on innovation?
  10. 10. “The majority of biopharma executives see the increasing market share of generics as a threat to companies in the industry and to investment in innovation.” Quintiles The New Health Report, 2010 A Survey of Biopharmaceutical Stakeholders in the New Health
  11. 11. 81% 78% 46% Failure of some biopharma companies Decline in investment in new therapies Worsening of public health 81% 78% 46% Failure of some biopharma companies Decline in investment in new therapies Worsening of public health How likely are each of the following to occur if generics continue to gain market share in biopharma? How likely are each of the following to occur if generics continue to gain market share in biopharma? Adopted from: The New Health Report A Survey of Biopharmaceutical Stakeholders in the New Health Quintiles, 2010 Biopharmaceutical Executive Survey Results
  12. 12. How will biosimilar companies impact innovation in the biopharmaceutical industry?
  13. 13. Defining the Innovation Space Radical Substantial Incremental Value-Add Newness Adopted from: www.ceoforum.com.au/articles.cfm?k=Invetech, February 2005 and Morgan S, Lopert R, Greyson D. Open Med. 2008; 2(a):e4-7. Commercial Comparative Effectiveness Gravity of Unmet Need Radical Substantial Incremental Biopharmaceutical
  14. 14. Where will biosimilar companies compete in this innovation space? Value-Add Newness Radical Substantial Incremental Biosimilar companies will compete in the areas of Incremental and Substantial innovation
  15. 15. The Competitive Nature of the Biosimilars Space Will Lead Companies to Innovate Fully and Aggressively Around Products and Processes  Process – Manufacturing – Clinical development – Process development  Product – Quality – Dosage form – Stability – Packaging – Customer convenience and safety  Strategy – Commercial – Regulatory and IP – Development – Supply Chain – Distribution Innovation
  16. 16. Layered Incremental Innovations Will Offer Substantial Innovation Value to Patients and Customers Substantial Incremental Value-Add Newness Biosimilar Innovation Space
  17. 17. Innovation Project Portfolios Must be Carefully Managed to Ensure They Drive Value Substantial Incremental Value-Add Newness Biosimilar Innovation Space Substantial Incremental Substantial Incremental Newness Newness Value-AddValue-Add
  18. 18. What are the trends among biopharmaceutical companies in this innovation space? Radical Substantial Incremental Value-Add Newness “Companies are raising their emphasis on the conservative end of the innovation spectrum” Innovation 2010: A Return to Prominence-and the Emergence of a New World Order A BCG Senior Management Survey, January 2010
  19. 19. 0 25 50 75 100 2007 2008 2009 2010 Boston Consulting Group 2010 Innovation Survey Results New-to-the-world offerings New offerings that allow expansion into new customer groups New offerings for existing customers Minor changes to existing offerings Cost reductions for Existing offerings Percentage of Pharma respondents selecting ‘important’ or ‘very important’ +78%+78% +12%+12%
  20. 20. A few closing thoughts on the potential dark side of innovation
  21. 21. 0 200 400 600 800 1000 2004 2005 2006 2007 2008 Prior Approval Non-Prior Approval Total +38%+38% BLA Manufacturing Supplements: Are we choking the FDA with “innovation”? Prior approval BLA manufacturing supplements increased 38% and reached a 5-year high of 333 in 2008 Prior approval BLA manufacturing supplements increased 38% and reached a 5-year high of 333 in 2008 Source: 2008 FDA PDUFA Performance Report
  22. 22. Conclusions  Biosimilars represent a distinct new sector of the biopharmaceutical industry  The emergence of the biosimilars sector is driving increased competition and enhanced innovation around biologic products and processes  Biosimilar companies will compete primarily in the incremental and substantial areas of the innovation space
  23. 23. Conclusions  Layered incremental innovations will result in meaningful cost reductions and enhanced product offerings for patients and customers  Over the past several years biopharmaceutical companies have increased their emphasis on conservative innovation projects – Biosimilars competition may encourage companies to reverse this trend  Innovation project portfolios should be carefully managed to ensure the best use of industry and health authority resources
  24. 24. Acknowledgments Special thanks to Boston Consulting Group for providing unpublished data and analyses

×